Developer docs
API playgroundTry for free, no card

Search company profiles

HRA Pharma

Full company profile

uuid0009g5t

Namestring
HRA Pharma
Legal namestring
HRA Pharma
Websiteurl
hra-pharma.com
Company typeenum
Private
Founded yearint
1996
Descriptiontext

HRA Pharma is a Paris-based consumer self-care pharmaceutical company founded in 1996 that develops and markets over-the-counter medicines and prescription equivalents for conditions consumers can self-manage, with particular specialization in women's health and reproductive health. Its flagship product is EllaOne, an emergency contraception brand supported by dedicated patient information documentation. The company operated a distinct rare diseases division (HRA Pharma Rare Diseases) covering specialized therapeutic areas. Prior to 2022, HRA Pharma was an independent privately-held entity that raised capital from investors including Riverside Company, Astorg, and Goldman Sachs.

In May 2022, Perrigo Company plc (NYSE: PRGO) completed the acquisition of HRA Pharma, integrating the company's branded self-care portfolio into Perrigo's global consumer self-care organization and leveraging Perrigo's retail and pharmacy distribution network across 20+ countries. In October 2024, Perrigo divested the HRA Pharma Rare Diseases business to Spain-based Esteve Pharmaceuticals S.A., separating rare disease operations from the core consumer self-care franchise. The leadership team includes a CEO, CFO, Chief Scientific Officer, Chief Global Commercial Officer, Chief Human Resources & Communication Officer, and Chief Corporate Development & Strategy Officer, and headcount is reported in the 51-100 range. HRA Pharma's business model is product sales of consumer pharmaceutical brands through retail and pharmacy channels; revenue mechanics now flow through Perrigo's global distribution infrastructure rather than direct-to-consumer channels.

Short descriptiontext

HRA Pharma is a Paris-founded consumer self-care pharmaceutical company specializing in over-the-counter and women's health products, notably the EllaOne emergency contraception brand. It operates as a subsidiary of Perrigo following the May 2022 acquisition, with rare disease operations divested to Esteve in October 2024.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersChâtillon, France
HQ citystring
Châtillon
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Keyword5 values
over-the-counter medicines, emergency contraception, consumer self-care, women's health products, reproductive health pharmaceuticals
Industry3 codes
PRIMARYHLAIACAN
Women’s Health & Reproductive Specialty Pharmaceuticals
SECONDARYHLAIAAAJ
Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing32541
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Consumer Pharmaceuticals (Women's Health)
Social media profiles2 records
Revenue model1 record
1Consumer Self-Care Products
TypeOne Time License
Description

HRA Pharma developed and marketed consumer self-care pharmaceutical products, including over-the-counter medicines and prescription equivalents for conditions that can be self-managed.

perrigo.com
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Supply Chain, Marketing or Sales, Operations, Personnel
GTM typeB2C
B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

HRA Pharma develops, manufactures, and markets consumer self-care pharmaceutical products focused on women's health and reproductive health. Its primary offering is EllaOne, an emergency contraception product sold over the counter. The company also operated a rare diseases division (divested to Esteve Pharmaceuticals in October 2024). Following Perrigo's May 2022 acquisition, HRA Pharma products are distributed through Perrigo's global retail and pharmacy channel network.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

HRA Pharma is a pharmaceutical company that was part of Perrigo's consumer self-care portfolio following the May 2022 acquisition. The company specializes in consumer health products and had a rare diseases division. Notable products include EllaOne (emergency contraception). In October 2024, Esteve Pharmaceuticals acquired HRA Pharma Rare Diseases from Perrigo. The product portfolio spans women's health and other consumer healthcare categories.

Product and service2 records
1EllaOne
CategoryEmergency contraception (women's health pharmaceutical)
Description

EllaOne is HRA Pharma's emergency contraception consumer pharmaceutical product, distributed over the counter through retail pharmacies and healthcare outlets across Perrigo's international markets, and supported by published Patient Information Leaflet (PIL) documentation for consumers.

2HRA Pharma Consumer Self-Care Product Portfolio
CategoryConsumer self-care pharmaceuticals (women's health and reproductive health)
Description

HRA Pharma's consumer self-care product portfolio spans women's health, including emergency contraception and other reproductive self-care pharmaceutical products, and is distributed across Europe and other international markets through Perrigo's regional pharmacy and retail outlet network.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeOthersAnnounced on2024-10-01
Description

In October 2024, Esteve Pharmaceuticals S.A. (Spain) acquired HRA Pharma Rare Diseases from Perrigo Company plc for an undisclosed sum. This transaction strengthened Esteve's rare disease portfolio and international expansion capabilities.

Strategic tierCoreTypeOthers
Description

Perrigo Company plc (NYSE: PRGO) completed the acquisition of HRA Pharma on May 02, 2022. HRA Pharma became part of Perrigo's consumer self-care product portfolio under the corporate structure at https://www.perrigo.com/hra-pharma.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Public women's health-focused pharmaceutical company spun out of Merck, with a portfolio spanning contraception, fertility, and reproductive health. Directly comparable to HRA Pharma as a branded specialty pharma anchored in women's reproductive health consumer products.

TypeDirect peer
Description

US-listed women's health pharmaceutical company commercializing branded prescription products in contraception, hormone therapy, and prenatal care. Comparable to HRA Pharma in its branded women's health go-to-market model and reliance on differentiated reproductive health products.

TypeBroad incumbent
Description

Diversified global life sciences company whose Consumer Health division includes leading women's health and reproductive products. Comparable to HRA Pharma as a large incumbent competing across women's health and consumer self-care categories with overlapping products such as oral contraceptives.

TypeBroad incumbent
Description

Major global pharmaceutical company with a women's health franchise including contraceptive and reproductive therapies. Comparable as a broad incumbent that competes with HRA Pharma in reproductive health while operating at significantly greater scale.

TypeEmerging player
Description

Smaller US-focused women's health company developing branded hormonal contraceptive products. Comparable to HRA Pharma as a niche branded player in women's reproductive health, though materially smaller and concentrated in the US market.

TypeEmerging player
Description

Women's health biotech commercializing branded contraceptives and sexual health products. Comparable to HRA Pharma as a smaller specialized reproductive health player competing in contraception and women's preventive health.

TypeDirect peer
Description

Global women's health specialty pharmaceutical company offering branded generics and innovative products across contraception, fertility, and maternal health. Comparable to HRA Pharma in focus, channel (pharmacy and consumer), and women's health self-care orientation.

TypeEmerging player
Description

Women's health-focused medical device and fertility company providing products across reproductive and contraceptive care. Comparable to HRA Pharma in the broader women's reproductive health category, though more focused on devices and fertility services than consumer pharma.

TypeBroad incumbent
Description

Large Indian-headquartered generics and specialty pharmaceutical company with a women's health portfolio including oral contraceptives. Comparable as a broad incumbent competing in women's reproductive health and consumer self-care categories across multiple geographies.

TypeEmerging player
Description

Women's health and prostate cancer focused biopharmaceutical company, now a subsidiary of Sumitomo Pharma. Comparable to HRA Pharma in its branded women's reproductive health focus, particularly uterine health and hormonal therapies.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment1 record

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

HRA Pharma

Consumer Pharmaceuticals (Women's Health)hra-pharma.com

HRA Pharma is a Paris-founded consumer self-care pharmaceutical company specializing in over-the-counter and women's health products, notably the EllaOne emergency contraception brand. It operates as a subsidiary of Perrigo following the May 2022 acquisition, with rare disease operations divested to Esteve in October 2024.

What HRA Pharma does

HRA Pharma is a Paris-based consumer self-care pharmaceutical company founded in 1996 that develops and markets over-the-counter medicines and prescription equivalents for conditions consumers can self-manage, with particular specialization in women's health and reproductive health. Its flagship product is EllaOne, an emergency contraception brand supported by dedicated patient information documentation. The company operated a distinct rare diseases division (HRA Pharma Rare Diseases) covering specialized therapeutic areas. Prior to 2022, HRA Pharma was an independent privately-held entity that raised capital from investors including Riverside Company, Astorg, and Goldman Sachs.

In May 2022, Perrigo Company plc (NYSE: PRGO) completed the acquisition of HRA Pharma, integrating the company's branded self-care portfolio into Perrigo's global consumer self-care organization and leveraging Perrigo's retail and pharmacy distribution network across 20+ countries. In October 2024, Perrigo divested the HRA Pharma Rare Diseases business to Spain-based Esteve Pharmaceuticals S.A., separating rare disease operations from the core consumer self-care franchise. The leadership team includes a CEO, CFO, Chief Scientific Officer, Chief Global Commercial Officer, Chief Human Resources & Communication Officer, and Chief Corporate Development & Strategy Officer, and headcount is reported in the 51-100 range. HRA Pharma's business model is product sales of consumer pharmaceutical brands through retail and pharmacy channels; revenue mechanics now flow through Perrigo's global distribution infrastructure rather than direct-to-consumer channels.

HRA Pharma firmographics

Firmographics
Name
HRA Pharma
Legal name
HRA Pharma
Website
https://hra-pharma.com
Company type
Private
Founded year
1996
Operating status
Acquired
Headcount range
101–250 employees
Short description
HRA Pharma is a Paris-founded consumer self-care pharmaceutical company specializing in over-the-counter and women's health products, notably the EllaOne emergency contraception brand. It operates as a subsidiary of Perrigo following the May 2022 acquisition, with rare disease operations divested to Esteve in October 2024.
Ownership category
akta.pro rank

HRA Pharma industry classification

Industry
Product category
Consumer Pharmaceuticals (Women's Health)
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIACAN
Women’s Health & Reproductive Specialty Pharmaceuticals
SECONDARYHLAIAAAJ
Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Over-the-counter medicines
  • Emergency contraception
  • Consumer self-care
  • Women's health products
  • Reproductive health pharmaceuticals

Where HRA Pharma is headquartered

Location

Headquarters

HQ city
Châtillon
HQ country
France
HQ region
Europe

Markets served

HRA Pharma business model

Business model
GTM type
B2C
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Supply Chain, Marketing or Sales, Operations, Personnel

Revenue model

  1. Consumer Self-Care Products: HRA Pharma developed and marketed consumer self-care pharmaceutical products, including over-the-counter medicines and prescription equivalents for conditions that can be self-managed.

Distribution channels1 record

Marketing channels1 record

HRA Pharma product offering

Product offering

Core offering

HRA Pharma develops, manufactures, and markets consumer self-care pharmaceutical products focused on women's health and reproductive health. Its primary offering is EllaOne, an emergency contraception product sold over the counter. The company also operated a rare diseases division (divested to Esteve Pharmaceuticals in October 2024). Following Perrigo's May 2022 acquisition, HRA Pharma products are distributed through Perrigo's global retail and pharmacy channel network.

Product overview

HRA Pharma is a pharmaceutical company that was part of Perrigo's consumer self-care portfolio following the May 2022 acquisition. The company specializes in consumer health products and had a rare diseases division. Notable products include EllaOne (emergency contraception). In October 2024, Esteve Pharmaceuticals acquired HRA Pharma Rare Diseases from Perrigo. The product portfolio spans women's health and other consumer healthcare categories.

Differentiator

Problem solved

Functional benefit

Products and services

  • EllaOne EllaOne is HRA Pharma's emergency contraception consumer pharmaceutical product, distributed over the counter through retail pharmacies and healthcare outlets across Perrigo's international markets, and supported by published Patient Information Leaflet (PIL) documentation for consumers.
  • HRA Pharma Consumer Self-Care Product Portfolio HRA Pharma's consumer self-care product portfolio spans women's health, including emergency contraception and other reproductive self-care pharmaceutical products, and is distributed across Europe and other international markets through Perrigo's regional pharmacy and retail outlet network.

Companies that use HRA Pharma

Customer profile

Segments1 record

Ideal customer profiles2 records

HRA Pharma technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

HRA Pharma partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Esteve Pharmaceuticals S.A.coreOthers · 1 October 2024In October 2024, Esteve Pharmaceuticals S.A. (Spain) acquired HRA Pharma Rare Diseases from Perrigo Company plc for an undisclosed sum. This transaction strengthened Esteve's rare disease portfolio and international expansion capabilities.
  • Perrigo Company plccoreOthersPerrigo Company plc (NYSE: PRGO) completed the acquisition of HRA Pharma on May 02, 2022. HRA Pharma became part of Perrigo's consumer self-care product portfolio under the corporate structure at https://www.perrigo.com/hra-pharma.

Scale indicators2 records

Recent moves5 records

Expansion highlights4 records

HRA Pharma competitors and assessment

Company assessment

Direct peers

  • Organon & Co. Public women's health-focused pharmaceutical company spun out of Merck, with a portfolio spanning contraception, fertility, and reproductive health. Directly comparable to HRA Pharma as a branded specialty pharma anchored in women's reproductive health consumer products.
  • TherapeuticsMD: US-listed women's health pharmaceutical company commercializing branded prescription products in contraception, hormone therapy, and prenatal care. Comparable to HRA Pharma in its branded women's health go-to-market model and reliance on differentiated reproductive health products.
  • Exeltis: Global women's health specialty pharmaceutical company offering branded generics and innovative products across contraception, fertility, and maternal health. Comparable to HRA Pharma in focus, channel (pharmacy and consumer), and women's health self-care orientation.

Broad incumbents

  • Bayer AG (Women's Health / Consumer Health): Diversified global life sciences company whose Consumer Health division includes leading women's health and reproductive products. Comparable to HRA Pharma as a large incumbent competing across women's health and consumer self-care categories with overlapping products such as oral contraceptives.
  • Pfizer Inc. (Women's Health portfolio): Major global pharmaceutical company with a women's health franchise including contraceptive and reproductive therapies. Comparable as a broad incumbent that competes with HRA Pharma in reproductive health while operating at significantly greater scale.
  • Lupin Pharmaceuticals: Large Indian-headquartered generics and specialty pharmaceutical company with a women's health portfolio including oral contraceptives. Comparable as a broad incumbent competing in women's reproductive health and consumer self-care categories across multiple geographies.

Emerging players

  • Agile Therapeutics: Smaller US-focused women's health company developing branded hormonal contraceptive products. Comparable to HRA Pharma as a niche branded player in women's reproductive health, though materially smaller and concentrated in the US market.
  • Evofem Biosciences: Women's health biotech commercializing branded contraceptives and sexual health products. Comparable to HRA Pharma as a smaller specialized reproductive health player competing in contraception and women's preventive health.
  • CooperSurgical: Women's health-focused medical device and fertility company providing products across reproductive and contraceptive care. Comparable to HRA Pharma in the broader women's reproductive health category, though more focused on devices and fertility services than consumer pharma.
  • Myovant Sciences (Sumitomo Pharma): Women's health and prostate cancer focused biopharmaceutical company, now a subsidiary of Sumitomo Pharma. Comparable to HRA Pharma in its branded women's reproductive health focus, particularly uterine health and hormonal therapies.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

HRA Pharma social profiles

Digital presence

HRA Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

HRA Pharma leadership team

Management profile

Number of profiles

Profiles6 records

HRA Pharma funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

HRA Pharma M&A and investment

M&A and investment

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about HRA Pharma

What does HRA Pharma do?

HRA Pharma develops, manufactures, and markets consumer self-care pharmaceutical products focused on women's health and reproductive health. Its primary offering is EllaOne, an emergency contraception product sold over the counter. The company also operated a rare diseases division (divested to Esteve Pharmaceuticals in October 2024). Following Perrigo's May 2022 acquisition, HRA Pharma products are distributed through Perrigo's global retail and pharmacy channel network.

Is HRA Pharma a public or private company?

HRA Pharma is a private company. It is classified as corporate owned and is currently acquired.

When was HRA Pharma founded?

HRA Pharma was founded in 1996. It employs 101 to 250 people.

Where is HRA Pharma based?

HRA Pharma is headquartered in Châtillon, France, in the Europe region.

How does HRA Pharma make money?

One revenue line is on record: consumer Self-Care Products.

Who are HRA Pharma's main competitors?

Direct peers on record are Organon & Co., TherapeuticsMD and Exeltis. Broad incumbents are Bayer AG (Women's Health / Consumer Health), Pfizer Inc. (Women's Health portfolio) and Lupin Pharmaceuticals. Emerging players are Agile Therapeutics, Evofem Biosciences, CooperSurgical and Myovant Sciences (Sumitomo Pharma).

Does HRA Pharma have an API?

No public API is recorded for HRA Pharma.

What industry is HRA Pharma in?

HRA Pharma's product category is Consumer Pharmaceuticals (Women's Health). Its primary akta.pro industry code is HLAIACAN, Women’s Health & Reproductive Specialty Pharmaceuticals, with a secondary code of HLAIAAAJ, Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health). Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
openPR.comMarket Driver Insights: The Impact of Recent Advances on the Adrenocortical Carcinoma MarketThe adrenocortical carcinoma market is projected to grow to $4.62 billion by 2030, representing a compound annual growth rate of 4.2%, driven by advancements in targeted therapies, minimally invasive surgeries, and improved early diagnosis. In October 2024, Esteve Pharmaceuticals S.A. (Spain) acquired HRA Pharma Rare Diseases from Perrigo Company plc for an undisclosed sum, strengthening its rare disease portfolio and international expansion capabilities. The market features multiple pharmaceutical companies actively involved in developing ACC treatments, including Roche, Merck, Bristol-Myers Squibb, AstraZeneca, and Pfizer.CNBCFDA approves Opill, the first over-the-counter birth control pillThe FDA approved Opill, the first over-the-counter birth control pill, on Thursday, manufactured by Paris-based HRA Pharma, a unit of Dublin-based Perrigo. The pill, generically norgestrel, will likely be sold at drugstores, convenience stores, grocery stores and online retailers in early 2024 with no age restrictions. Perrigo's stock rose 5% in early trading; pricing was not disclosed.AxiosFDA approves 1st over-the-counter daily birth control pillThe FDA approved the first over-the-counter daily birth control pill, Opill, from HRA Pharma. The decision allows U.S. access to join over 100 countries selling contraceptives without a prescription, with packs costing $20–$50. Perrigo expects Opill to be available online and in stores in the first quarter of 2024.AxiosFDA experts weigh OTC birth control amid agency staff skepticismFDA advisory committees will vote on making HRA Pharma's Opill birth control available over-the-counter, with staff concerned about patient misuse. The move could expand access for over 19 million women in areas lacking full contraceptive options, but anti-abortion groups oppose it. A final decision is expected this summer.AxiosFDA advisers will weigh over-the-counter birth control in MayFDA advisers will meet May 9-10 to consider making a contraceptive pill available without a prescription for the first time. HRA Pharma's Opill could generate $100 million in peak sales, but questions remain about cost and insurer coverage. Advocates have asked the government to clarify that ACA coverage applies to over-the-counter birth control.PR NewswirePerrigo Reports Fourth Quarter & Fiscal Year 2022 Financial Results From Continuing OperationsPerrigo Company plc reported fourth quarter 2022 net sales of $1.2 billion, up 4.6% year-over-year, and full fiscal year 2022 net sales of $4.5 billion, up 7.6%, with constant currency growth of 12.8%. The company achieved record quarterly net sales for both its Consumer Self-Care Americas and International segments, with adjusted diluted EPS of $0.75 for Q4 (up 25%) and $2.07 for the full year. In Q4, Perrigo completed the acquisition of Nestlé's Gateway infant formula facility and U.S. & Canadian GoodStart® brand, building on the earlier 2022 acquisition of HRA Pharma as part of its transformation into a pure-play consumer self-care company.AxiosThe road to making birth control pills over-the-counter in the U.S.The FDA advisory panel will meet on Nov. 18 to review HRA Pharma's application to make Opill birth control available without a prescription. Advocates say it could prevent unwanted pregnancies, but affordability and insurance coverage remain uncertain. The FDA's final decision is expected in 2023.AxiosFDA schedules meeting to review over-the-counter birth control pillThe FDA will hold a public meeting on Nov. 18 to review HRA Pharma's application to make Perrigo's Opill, a progestin-only birth control pill, available over the counter. The pill has been prescription-only since 1973, and the meeting involves two advisory committees. Insurance coverage remains uncertain.Business InsiderA first of its kind over-the-counter birth control pill is now seeking FDA approval. It comes just as the Supreme Court's Roe v. Wade decision heightens fears over contraception access.HRA Pharma is seeking FDA approval to sell an over-the-counter birth control pill in the US, the first of its kind since prescriptions were required. The company expects a decision in about 10 months, and the application comes after the Supreme Court overturned Roe v. Wade, raising concerns about contraceptive access.MedicalxpressFDA mulling over-the-counter sale of contraceptive pillHRA Pharma has submitted an application to the U.S. Food and Drug Administration to make its contraceptive pill, Opill, available over-the-counter without a prescription. Cadence Health is also in discussions with the FDA regarding similar access for its products, amidst heightened political debate following the Supreme Court's overturning of Roe v. Wade.